Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Carcinoma, Renal Cell
Interventions
BIOLOGICAL

TroVax

TroVax 1 x 10E9 TCID 50mL

DRUG

IL-2

IL-2 250,000 U/kg S/C for cycle 1 and day 1 of subsequent cycles, 125,000U/kg S/C for days 2-5 of cycles 2-6

Trial Locations (1)

77030

The Methodist Hospital, Houston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

ORION Clinical Services

INDUSTRY

lead

Oxford BioMedica

INDUSTRY